Skip to main content

Institutional intelligence for ALEMBIC PHARMACEUTICALS

Cross-view mutual fund activity and super-investor shareholding · Jun 2026 SHP.

Ownership breakdown

Category totals from the official quarterly Shareholding Pattern filing (Jun 2026). Sums to 100.00%.

  • Promoters69.87%
  • FII4.18%
  • Mutual Funds8.73%
  • DII (ex-MF)7.21%
  • Retail & others10.01%
  • 1% Club 8.13%(subset)

Super Investors and 1% Club names below are disclosed holders at or above 1%. They are subsets of the categories above, not additive. View filing

Holder details (≥1% disclosed names)

Promoters

Promoter & promoter group

69.87%4 named
HolderStakeSharesValue (₹ Cr)
35.78%7,03,31,810₹5.83k Cr
28.54%5,60,97,544₹4.65k Cr
2.13%41,92,529₹347.6 Cr
1.53%30,05,730₹249.2 Cr

1% Club — Individuals & others

Non-promoter ≥1% holders not matched to a curated profile

8.13%4 named
HolderStakeSharesValue (₹ Cr)
3.86%75,85,888₹628.9 Cr
1.74%34,27,766₹284.2 Cr
1.38%27,12,515₹224.9 Cr
1.15%22,64,405₹187.7 Cr

Retail & others

Holders below 1% disclosure threshold and public non-institutions

10.01%

SEBI requires naming only shareholders with ≥1% stake. The remaining 10.01% includes retail investors, small HNIs, employee trusts, and other holders below the disclosure threshold — aggregated in the official filing.

DII (other)

Insurance, banks, AIF, other domestic institutions

7.21%1 named
HolderStakeSharesValue (₹ Cr)
Tracked as LIC4.32%84,95,125₹704.3 Cr

Mutual Funds

Domestic mutual funds & UTI

8.73%No names

No named holders ≥1% in this bucket.

FII / FPI

Foreign portfolio investors

4.18%No names

No named holders ≥1% in this bucket.

Super Investors

Curated tracked investor profiles

No names

No curated super investor holds ≥1% in the latest filing. See FII, DII, and mutual fund holders in the sections above.

Shareholding data sourced from NSE/BSE regulatory filings. Category chart uses official filing totals; named holder lists include every disclosed ≥1% position. Not investment advice. See our disclaimer and methodology.